Nancy Lurker - 03 Jan 2025 Form 4 Insider Report for EyePoint Pharmaceuticals, Inc. (EYPT)

Role
Director
Signature
/s/ Ron Honig, Attorney-in-Fact
Issuer symbol
EYPT
Transactions as of
03 Jan 2025
Net transactions value
$0
Form type
4
Filing time
07 Jan 2025, 16:04:08 UTC
Previous filing
20 Aug 2024
Next filing
05 Feb 2025

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EYPT Common Stock Options Exercise $0 +12,667 +13% $0.000000 110,302 05 Jan 2025 Direct
transaction EYPT Common Stock Options Exercise $0 +75,134 +68% $0.000000 185,436 06 Jan 2025 Direct
holding EYPT Common Stock 126,889 03 Jan 2025 By Family Trust F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EYPT Stock Option (Right to Buy) Award $0 +40,000 $0.000000 40,000 03 Jan 2025 Common Stock 40,000 $8.26 Direct
transaction EYPT Restricted Stock Units Options Exercise $0 -12,667 -33% $0.000000 25,333 05 Jan 2025 Common Stock 12,667 $0.000000 Direct F2
transaction EYPT Restricted Stock Units Options Exercise $0 -75,134 -50% $0.000000 75,133 06 Jan 2025 Common Stock 75,134 $0.000000 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These securities are held in a trust for the benefit of the reporting person's children. The reporting person's spouse is trustee of the Family Trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
F2 The restricted stock units vests in three ratable annual installments beginning January 5, 2025.
F3 The restricted stock units vests in three ratable annual installments beginning January 6, 2024.